Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.61 USD | +0.56% | +5.71% | +35.99% |
May. 02 | Organon's Q1 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance, Quarterly Dividend Maintained | MT |
May. 02 | Transcript : Organon & Co., Q1 2024 Earnings Call, May 02, 2024 |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Its low valuation, with P/E ratio at 6.41 and 5.15 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- One of the major weak points of the company is its financial situation.
- The company appears highly valued given the size of its balance sheet.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+35.99% | 5.01B | B | ||
+26.08% | 681B | C+ | ||
+21.85% | 556B | B | ||
-4.77% | 361B | C+ | ||
+16.97% | 325B | B- | ||
+5.69% | 285B | C+ | ||
+13.68% | 235B | B+ | ||
+3.65% | 199B | B- | ||
-11.12% | 189B | A+ | ||
-3.40% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OGN Stock
- Ratings Organon & Co.